|
Oct 9
|
Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds
|
|
Oct 8
|
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
|
|
Sep 11
|
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
|
|
Sep 10
|
Ionis announces pricing of $500.3 million public offering
|
|
Sep 9
|
Ionis announces proposed public offering of common stock
|
|
Sep 5
|
Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?
|
|
Sep 4
|
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
|
|
Sep 4
|
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
|
|
Sep 4
|
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
|
|
Jul 31
|
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
|
|
Jul 30
|
Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Jul 25
|
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Jul 23
|
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
|
|
Jul 23
|
Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug
|
|
Jul 22
|
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
|
|
Jul 12
|
Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?
|
|
Jul 8
|
Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
|
|
Jun 26
|
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
|
|
Jun 25
|
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
|
|
Jun 25
|
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
|